Institution
University Of Tennessee System
Education•Knoxville, Tennessee, United States•
About: University Of Tennessee System is a education organization based out in Knoxville, Tennessee, United States. It is known for research contribution in the topics: Population & Health care. The organization has 741 authors who have published 585 publications receiving 36866 citations. The organization is also known as: UT System.
Topics: Population, Health care, Lepton, Cancer, Muon
Papers published on a yearly basis
Papers
More filters
Emory University1, University of Pittsburgh2, Riverside Methodist Hospital3, University of Miami4, Autonomous University of Barcelona5, Centre Hospitalier Universitaire de Toulouse6, Baptist Health7, Case Western Reserve University8, University at Buffalo9, Royal Melbourne Hospital10, Rush University Medical Center11, California Pacific Medical Center12, University Health Network13, University Of Tennessee System14, University of Kansas15, University of Barcelona16, Capital District Health Authority17, Kaiser Permanente18, University of California, Los Angeles19, University of California, San Francisco20
TL;DR: Among patients with acute stroke who had last been known to be well 6 to 24 hours earlier and who had a mismatch between clinical deficit and infarct, outcomes for disability at 90 days were better with thrombectomy plus standard care than with standard care alone.
Abstract: BackgroundThe effect of endovascular thrombectomy that is performed more than 6 hours after the onset of ischemic stroke is uncertain. Patients with a clinical deficit that is disproportionately severe relative to the infarct volume may benefit from late thrombectomy. MethodsWe enrolled patients with occlusion of the intracranial internal carotid artery or proximal middle cerebral artery who had last been known to be well 6 to 24 hours earlier and who had a mismatch between the severity of the clinical deficit and the infarct volume, with mismatch criteria defined according to age (<80 years or ≥80 years). Patients were randomly assigned to thrombectomy plus standard care (the thrombectomy group) or to standard care alone (the control group). The coprimary end points were the mean score for disability on the utility-weighted modified Rankin scale (which ranges from 0 [death] to 10 [no symptoms or disability]) and the rate of functional independence (a score of 0, 1, or 2 on the modified Rankin scale, whic...
3,331 citations
University of Alabama at Birmingham1, University of South Florida2, Vanderbilt University3, City of Hope National Medical Center4, Fox Chase Cancer Center5, University Of Tennessee System6, Brigham and Women's Hospital7, Seattle Cancer Care Alliance8, Case Western Reserve University9, Roswell Park Cancer Institute10, Northwestern University11, Harvard University12, University of Nebraska Medical Center13, University of Utah14, Memorial Sloan Kettering Cancer Center15
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Abstract: Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions in the breast ducts. The goal for management of DCIS is to prevent the development of invasive breast cancer. This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
1,545 citations
Johns Hopkins University1, Seattle Cancer Care Alliance2, University of Colorado Boulder3, University of Utah4, Fox Chase Cancer Center5, Brigham and Women's Hospital6, Duke University7, Northwestern University8, University of South Florida9, University of Alabama at Birmingham10, Washington University in St. Louis11, University of California, San Francisco12, Roswell Park Cancer Institute13, Vanderbilt University14, University of Texas MD Anderson Cancer Center15, Harvard University16, University of Wisconsin-Madison17, Yale Cancer Center18, University of Michigan19, Stanford University20, Ohio State University21, City of Hope National Medical Center22, Memorial Sloan Kettering Cancer Center23, Mayo Clinic24, Case Western Reserve University25, University Of Tennessee System26
TL;DR: This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastasis disease.
Abstract: This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.
1,003 citations
Fox Chase Cancer Center1, University of Utah2, University of Texas MD Anderson Cancer Center3, University of California, San Diego4, University of South Florida5, Brigham and Women's Hospital6, University of Alabama at Birmingham7, Roswell Park Cancer Institute8, Case Western Reserve University9, Ohio State University10, University of Colorado Boulder11, University of Nebraska Medical Center12, Johns Hopkins University13, University of California, San Francisco14, University Of Tennessee System15, City of Hope National Medical Center16, University of Washington17, Duke University18, Northwestern University19, Memorial Sloan Kettering Cancer Center20
TL;DR: This portion of the NCCN Guidelines discusses general principles for the diagnosis, staging, and treatment of STS of the extremities, superficial trunk, or head and neck; outlines treatment recommendations by disease stage; and reviews the evidence to support the guidelines recommendations.
Abstract: Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Guidelines for STS provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as intra-abdominal/retroperitoneal STS, gastrointestinal stromal tumors, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis, staging, and treatment of STS of the extremities, superficial trunk, or head and neck; outlines treatment recommendations by disease stage; and reviews the evidence to support the guidelines recommendations.
894 citations
Journal Article•
University of Minnesota1, University of Virginia2, Memorial Hospital of Rhode Island3, University of Rochester4, University Of Tennessee System5, Baylor College of Medicine6, University of Michigan7, Cincinnati Children's Hospital Medical Center8, Albany Medical College9, State University of New York Upstate Medical University10, University of California, San Francisco11
856 citations
Authors
Showing all 748 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Robert Stone | 160 | 1756 | 167901 |
| Christopher P. Cannon | 151 | 1118 | 108906 |
| Sevil Salur | 147 | 1470 | 106407 |
| Yuri Gershtein | 139 | 1558 | 104279 |
| Eva Halkiadakis | 137 | 1604 | 97953 |
| Amitabh Lath | 135 | 1646 | 97861 |
| Elliot Hughes | 134 | 1404 | 97687 |
| Alex J. Barker | 132 | 1273 | 84746 |
| Andrea Castro | 132 | 1500 | 90019 |
| Scott Thomas | 131 | 1219 | 85507 |
| John Paul Chou | 131 | 1193 | 82912 |
| Keith Rose | 129 | 876 | 75970 |
| Dinko Ferencek | 128 | 1161 | 79410 |
| Christian Contreras-Campana | 124 | 987 | 70668 |
| Daniel Duggan | 124 | 778 | 66716 |